|
US 7,320,961 B2 |
|
Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate |
Dale J. Kempf, Libertyville, Ill. (US); Richard J. Bertz, Kenosha, Wis. (US); and Jeffrey F. Waring, Franklin, Wis. (US) |
Assigned to Abbott Laboratories, Abbott Park, Ill. (US) |
Filed on Mar. 18, 2004, as Appl. No. 10/802,829. |
Claims priority of provisional application 60/457138, filed on Mar. 24, 2003. |
Prior Publication US 2004/0242509 A1, Dec. 02, 2004 |
Int. Cl. A61K 31/425 (2006.01); A61K 38/00 (2006.01)
|